Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
16.76
-0.69 (-3.95%)
At close: Feb 27, 2026, 4:00 PM EST
16.75
-0.01 (-0.06%)
After-hours: Feb 27, 2026, 7:58 PM EST
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for Sarepta Therapeutics stock have an average target of 25.48, with a low estimate of 5.00 and a high estimate of 81. The average target predicts an increase of 52.03% from the current stock price of 16.76.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock from 28 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 8 | 7 | 7 | 7 | 7 | 7 |
| Hold | 13 | 13 | 13 | 13 | 13 | 13 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 4 | 4 | 4 | 4 | 4 | 4 |
| Total | 30 | 29 | 29 | 28 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $45 → $38 | Buy | Maintains | $45 → $38 | +126.73% | Feb 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $5 | Strong Sell | Reiterates | $5 | -70.17% | Jan 27, 2026 |
| Wedbush | Wedbush | Buy Maintains $32 → $34 | Buy | Maintains | $32 → $34 | +102.86% | Jan 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $5 | Strong Sell | Reiterates | $5 | -70.17% | Jan 14, 2026 |
| Wedbush | Wedbush | Buy Initiates $32 | Buy | Initiates | $32 | +90.93% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
1.63B
from 2.20B
Decreased by -25.94%
Revenue Next Year
1.55B
from 1.63B
Decreased by -4.79%
EPS This Year
2.78
from -7.13
EPS Next Year
2.58
from 2.78
Decreased by -7.17%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.3B | 2.0B | |||
| Avg | 1.6B | 1.6B | |||
| Low | 1.3B | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.8% | 20.9% | |||
| Avg | -25.9% | -4.8% | |||
| Low | -40.9% | -30.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.06 | 4.85 | |||
| Avg | 2.78 | 2.58 | |||
| Low | 0.47 | 1.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 74.4% | |||
| Avg | - | -7.2% | |||
| Low | - | -56.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.